Articles from Invizyne Technologies, Inc.

Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025
By Invizyne Technologies, Inc. · Via GlobeNewswire · February 10, 2025

Project is part of the U.S. Department of Defense’s BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development
By Invizyne Technologies, Inc. · Via GlobeNewswire · November 19, 2024

Monrovia, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the closing of its initial public offering of 1,875,000 shares of its common stock at a public offering price of $8.00 per share. The shares began trading on NASDAQ under the ticker symbol “IZTC” on November 13, 2024.
By Invizyne Technologies, Inc. · Via GlobeNewswire · November 14, 2024

Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology
By Invizyne Technologies, Inc. · Via GlobeNewswire · November 13, 2024

Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC"
By Invizyne Technologies, Inc. · Via GlobeNewswire · November 13, 2024

Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC"
By Invizyne Technologies, Inc. · Via GlobeNewswire · November 12, 2024

Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC”
By Invizyne Technologies, Inc. · Via GlobeNewswire · November 11, 2024

By Invizyne Technologies, Inc. · Via GlobeNewswire · May 7, 2024

Monrovia, CA, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC, (NASDAQMDBH) ("MDB") – today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") for the sale of its common stock in a firm commitment public offering.
By Invizyne Technologies, Inc. · Via GlobeNewswire · February 12, 2024

Monrovia, CA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC, (NASDAQMDBH) ("MDB") – today announced the appointment of Michael Burns to its senior leadership team as Executive Vice President, Energy Transition.
By Invizyne Technologies, Inc. · Via GlobeNewswire · November 8, 2023

Non-Dilutive Funding and Resources Provided to De-Risk Investment and Accelerate Commercialization
By Invizyne Technologies, Inc. · Via GlobeNewswire · October 17, 2023

Funding Supports Project to Optimize and Scale Up Isobutanol Production to Address Potential $27.4 Billion Sustainable Aviation Fuel Market
By Invizyne Technologies, Inc. · Via GlobeNewswire · October 11, 2023